Article Sidebar

PDF (Tiếng Việt)
Published: 2024-02-27
Abstract Views: 161
Views PDF (Tiếng Việt): 136
DOI: https://doi.org/10.52852/tcncyh.v174i1.2152
Issue
Vol. 174 No. 1 (2024)
Section
Các bài báo
How to Cite
Khuyên, P. H. ., Doãn, H. Đình ., Huề, N. D. ., Dũng, L. T. ., & Hoài, N. V. . (2024). 13. Factors influencing post-embolization syndrome in hepatocellular carcinoma treatment using lipiodol. Journal of Medical Research, 174(1), 110-116. https://doi.org/10.52852/tcncyh.v174i1.2152

13. Factors influencing post-embolization syndrome in hepatocellular carcinoma treatment using lipiodol

Pham Huu Khuyen, Hoang Dinh Doan, Nguyen Duy Hue, Le Thanh Dung, Ngo Vinh Hoai

Main Article Content

Abstract

Transarterial chemoembolization (TACE) is a widely used method for treatment of hepatocellular carcinoma nowadays with safety and efficacy. Postembolization syndrome (PES) is a frequently side effect of TACE, and often is the cause of protracted recovery of patients. Our prospective study was performed on 663 TACE procedures at Viet Duc Hospital from 08/2022 to 07/2023. The result showed that previous history of PES, and other related factors influencing PES treatment were the number of tumors, the feeding arteries of the tumor, the tumor size, the level of selective injury and the level of lipiodol selected.

Article Details

Keywords

Postembolization syndrome, Transarterial chemoembolization, hepatocellular carcinoma, lipiodol

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatol Baltim Md. 2016;64(1):106-116. doi:10.1002/hep.28453
3. Prajapati HJ, Rafi S, El-Rayes BF, et al. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J Vasc Interv Radiol JVIR. 2012;23(10):1286-1293.e1. doi:10.1016/j.jvir.2012.07.003
4. Blackburn H, West S. Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs. 2016;39(5):E1-E18. doi:10.1097/NCC.00 00000000000302
5. Nasser F, Cavalcante RN, Galastri FL, et al. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. J Vasc Interv Radiol JVIR. 2014;25(7):1012-1017. doi:10.1016/j.jvir.2014.02.025
6. Khalaf MH, Sundaram V, AbdelRazek Mohammed MA, et al. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma. Radiology. 2019;290(1):254-261. doi:10.1148/radiol.2018180257
7. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. doi:10.1002/bjs.1800600817
8. He JJ, Yin XX, Wang T, et al. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization. J Cancer Res Ther. 2021;17(3):777-783. doi:10.4103/jcrt.jcrt_132_ 21
9. Arslan M, Degirmencioglu S. Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization. Curr Med Imaging Former Curr Med Imaging Rev. 2019;15(4):380-385. doi:10.2174/1573405615666181122145330
10. Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis. Cardiovasc Intervent Radiol. 1994;17(2):76-80. doi:10.1007/BF00193921